Lanzhou, China – Foci Pharmaceutical, a Chinese pharmaceutical company, has successfully completed the experimental production of two antiviral remedies, Qihuang B苇瘟方 and Xuanfei Huazhu 汤剂，in response to the ongoing COVID-19 pandemic. The company is now poised to scale up production and make these remedies available to the market.
In line with the stringent requirements of the Lanzhou Municipal COVID-19 Comprehensive防控 Office and the Municipal Health Commission, Foci Pharmaceutical was tasked with manufacturing the Traditional Chinese Medicine (TCM) formulations as outlined in the Gansu Province TCM Prevention of COVID-19 Formulas (2021 Edition). The task was assigned to the company on October 30, and within a short span of time, Foci Pharmaceutical mobilized its resources to meet the urgent demand.
To ensure the quality of the products, the quality department of Foci Pharmaceutical conducted rigorous inspections of the raw materials and promptly issued the test results. The company’s quality management and research and development team worked tirelessly to complete the laboratory-scale trials of the two remedies, providing reliable quality control data for large-scale production.
The two remedies, Qihuang B苇瘟方 and Xuanfei Huazhu 汤剂, are based on the traditional Chinese medicine theory and have been shown to have antiviral properties. They are believed to help in preventing and treating COVID-19, and are part of the ongoing efforts to combat the pandemic in China.
According to the company, the first batch of Qihuang B苇瘟方 and Xuanfei Huazhu 汤剂 was successfully produced on the evening of October 30, and the products will now be available for mass production and distribution to meet the needs of the citizens of Lanzhou.
Foci Pharmaceutical’s commitment to the health and well-being of the public is evident in its swift response to the COVID-19 pandemic. The company’s efforts to develop and produce these antiviral remedies are a testament to its dedication to public service and its role as a responsible pharmaceutical company in China.
The experimental production of these remedies is a significant milestone in the fight against the COVID-19 pandemic. It highlights the importance of traditional Chinese medicine in the ongoing efforts to combat the virus and provides hope for a brighter future.
As the pandemic continues to unfold, the successful production and distribution of these antiviral remedies by Foci Pharmaceutical demonstrate the power of innovation and collaboration in the fight against COVID-19. The company’s efforts are a shining example of how the pharmaceutical industry can play a crucial role in protecting public health during these challenging times.
In conclusion, Foci Pharmaceutical’s achievement in completing the experimental production of Qihuang B苇瘟方 and Xuanfei Huazhu 汤剂 is a significant step forward in the fight against the COVID-19 pandemic. As these remedies become more widely available, they have the potential to make a meaningful impact on the health and well-being of the Chinese people and contribute to the global effort to combat the virus.
Views: 0